How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and resource savings reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis

Closed for comments This consultation ended on at   Request commenting lead permission

5 Minimum evidence standards

During the evidence generation period new technologies may become available. This section summarises the minimum evidence requirements that a new technology would need to meet to be considered in NICE's evaluation after the evidence generation period.

The committee noted that the digital technologies have comparable clinical effectiveness for managing mild to moderate symptoms of hip or knee osteoarthritis in comparison with conventional management of these conditions, but evidence for this is uncertain. It heard that the technologies may increase access to treatment in some populations and reduce the demand of in-person GP or physiotherapy appointments, but evidence for this was also limited.

For new technologies, the committee has indicated that it may, in future, be able to recommend technologies in this topic area that have UK-based evidence for:

  • non-inferiority of the digital platforms compared with conventional management of the condition in terms of clinical effectiveness

  • user engagement with the technology, including intervention acceptance, usability and completion rates

  • cost savings resulting from resource use associated with the technologies.

Companies can strengthen the evidence base by also having evidence for uptake rates in different subpopulations.